Amphastar Pharmaceuticals, Inc. (AMPH) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
Portfolio Pulse from
Levi & Korsinsky is investigating Amphastar Pharmaceuticals, Inc. for potential violations of federal securities laws after the company received a secondary complete response letter from the FDA for its generic teriparatide ANDA, AMP-015.
February 24, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals is under investigation for potential securities law violations after receiving a secondary CRL from the FDA for its generic teriparatide, AMP-015.
The investigation by Levi & Korsinsky and the FDA's secondary CRL for AMP-015 suggest potential legal and regulatory challenges for Amphastar, likely impacting investor sentiment negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100